A Population-Based Study of the Incidence and Complication Rates of Herpes Zoster Before Zoster Vaccine Introduction
Mayo Clinic ProceedingsPublished 1 November 2007
Barbara P. Yawn, Patricia Saddier, Peter C. Wollan, Jennifer L. St. Sauver, Marge Kurland, Lina S. Sy
Citations858
SJR quartileQ1
SJR score2.00
SNIP2.28
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
The authors' population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
Abstract
Our population-based data suggest that HZ primarily affects immunocompetent adults older than 50 years; 1 in 4 experiences some type of HZ-related complication.
Keywords
Medicine
New England Journal of MedicineA Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
2,393 Citations2005Michael N. Oxman, Myron J. Levin +48 more
JAMATrends in Heart Failure Incidence and Survival in a Community-Based Population
1,595 Citations2004Véronique L. Roger
In this community-based cohort, the incidence ofheart failure has not declined during 2 decades, but survival after onset of heart failure has increased overall, with less improvement among women and elderly persons.
Mayo Clinic ProceedingsHistory of the Rochester Epidemiology Project
1,453 Citations1996L. Joseph Melton
The Rochester Epidemiology Project is a unique medical records-linkage system that encompasses the care delivered to residents of Rochester and Olmsted County, Minnesota and is able to provide accurate incidence data for almost any serious condition and to support population-based analytic studies of disease causes and outcomes.
JAMAGabapentin for the Treatment of Postherpetic Neuralgia<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
1,433 Citations1998Michael C. Rowbotham
Gabapentin is effective in the treatment of pain and sleep interference associated with PHN and Mood and quality of life also improve with gabapentin therapy.
Proceedings of the Royal Society of MedicineThe Nature of Herpes Zoster: A Long-Term Study and a New Hypothesis
1,266 Citations1965R. Edgar Hope-Simpson
Herpes zoster represents an adaptation enabling varicella virus to survive for long periods, even without a continuous supply of persons susceptible to chickenpox.
MedicinePopulation-Based Study of Herpes Zoster and Its Sequelae
928 Citations1982M. W. RAGOZZINO, L. Joseph Melton +3 more
The dermatomal distribution of herpes zoster observed in Rochester was quite similar to previous studies, despite their inherent biases in case ascertainment, except for a lower proportion with cranial nerve zoster.
Clinical Infectious DiseasesRecommendations for the Management of Herpes Zoster
845 Citations2006Robert H. Dworkin, Robert W. Johnson +21 more
The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacy Clovir as first-line antiviral therapy for the treatment of patients with HZ.
NeurologyPregabalin for the treatment of postherpetic neuralgia
762 Citations2003Robert H. Dworkin, A. Corbin +6 more
Treatment of postherpetic neuralgia with pregabalin is safe, efficacious in relieving pain and sleep interference, and associated with greater global improvement than treatment with placebo.
Archives of Internal MedicineThe Incidence of Herpes Zoster
621 Citations1995James G. Donahue
The recorded incidence of herpes zoster was 64% higher than that reported 30 years ago; the age-standardized rate was more than twofold higher and immunosuppressive conditions had little impact on overall incidence, although they were strongly associated with early recurrences.
PainGabapentin in postherpetic neuralgia: a randomised, double blind, placebo controlled study
593 Citations2001Andrew S.C. Rice, S. Maton
The role of gabapentin as an efficacious and well‐tolerated treatment for postherpetic neuralgia is confirmed and the most common adverse events were dizziness and somnolence, particularly during the titration phase.
PainPregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial
524 Citations2004R. Sabatowski, Rafael Gálvez +5 more
Health‐related quality‐of‐life (HRQoL) measurements using the SF‐36 Health Survey demonstrated improvement in the mental health domain for both pregabalin dosages, and bodily pain and vitality domains were improved in the 300 mg/day group.
Journal of General Internal MedicineThe incidence of herpes zoster in a United States administrative database
484 Citations2005Ralph P. Insinga, Robbin Itzler +3 more
The overall incidence of HZ reported in the present study was found to be similar to rates observed in U.S. analyses conducted 10 to 20 years earlier, after age- and sex-standardizing estimates from all studies to the 2000 U.s. population.
Epidemiology and InfectionEpidemiology of varicella zoster virus infection in Canada and the United Kingdom
431 Citations2001Marc Brisson, W. John Edmunds +6 more
A comprehensive picture of the pre-vaccine epidemiology of the varicella zoster virus (VZV) is provided to aid in the design of immunization programs and to adequately measure the impact of vaccination.
Archives of DermatologyThe Outcome of Patients with Herpes Zoster
371 Citations1957J.M. de Moragas
There is a continuous stream of publications, in the medical literature, devoted to the study of the results obtained in the treatment of herpes zoster, and no single method of treatment has produced more than temporary enthusiasm.
VaccineExposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox
336 Citations2002Marc Brisson, N Gay +2 more
It is shown that exposure to varicella is greater in adults living with children and that this exposure is highly protective against zoster, and under the 'best-fit' model, Exposure to varICElla is estimated to boost cell-mediated immunity for an average of 20 years.
Clinical Infectious DiseasesHerpes Zoster in Older Adults
330 Citations2001Thomas T. Yoshikawa, Kenneth E. Schmader
Key age-related clinical, epidemiological, and treatment features of zoster and PHN are reviewed and attempts to reduce or eliminate HZ pain have been bolstered by the findings of clinical trials that antiviral agents and corticosteroids are effective treatment for HZ and that tricyclic antidepressants, topical lidocaine, gabapentin, and opiates areeffective treatment for PHN.
Clinical Infectious DiseasesOral Acyclovir Therapy Accelerates Pain Resolution in Patients with Herpes Zoster: A Meta-analysis of Placebo-Controlled Trials
328 Citations1996Marsha Wood, R. Kay +3 more
Acyclovir was clearly shown to accelerate pain resolution by all of the measures employed, and benefit was especially evident in patients 50 years of age or older.
The Journal of Infectious DiseasesIncidence of Herpes Zoster, Before and After Varicella‐Vaccination–Associated Decreases in the Incidence of Varicella, 1992–2002
286 Citations2005Aisha O. Jumaan, Onchee Yu +4 more
The findings revealed that the vaccination-associated decrease in varicella disease did not result in an increase in the incidence of HZ, and these early findings will have to be confirmed as the occurrence of varICElla disease continues to decrease.
Epidemiology and InfectionModelling the impact of immunization on the epidemiology of varicella zoster virus
268 Citations2000Marc Brisson, W. John Edmunds +3 more
Adding a catch-up campaign in the first year for 1–11 year olds seems to be the most effective strategy to reduce both varicella incidence and morbidity (in the short and long term), though with the possible detrimental effect of increasing the incidence of zoster.
Clinical Infectious DiseasesAcute Pain in Herpes Zoster and Its Impact on Health-Related Quality of Life
258 Citations2004Jennifer Katz, Erin Mentuch Cooper +3 more
It is found that greater pain burden, as assessed by the product of pain intensity and duration, was associated with poorer physical functioning, increased emotional distress, and decreased role and social functioning.
Family PracticeHerpes zoster and postherpetic neuralgia: incidence and risk indicators using a general practice research database
227 Citations2002Wim Opstelten
Preventive strategies should focus on patients with herpes zoster aged >55 years and with ophthalmic localization, as the risk of developing PHN increases with age.
New England Journal of MedicineVaricella–Zoster Vaccine for the Prevention of Herpes Zoster
167 Citations2007David W. Kimberlin, Richard J. Whitley
A 64-year-old man in good general health presents to his internist for a routine examination and is told that in a large clinical trial, the varicella–zoster vaccine reduced the incidence of herpes zoster by 51% andThe incidence of postherpetic neuralgia by 67%.
Epidemiology and InfectionIncidence of herpes zoster, 1997–2002
166 Citations2005John P. Mullooly, Karen Riedlinger +3 more
There were significant increases in HZ incidence rates in Oregon and Washington during 1997–2002 among children aged 10–17 years, associated with increased exposure to oral steroids.
Journal of Medical VirologyEpidemiology of varicella-zoster virus in England and Wales
149 Citations2003Marc Brisson, W. John Edmunds
The objective of this study was to provide a complete picture of the pre‐vaccine epidemiology of the Varicella‐Zoster Virus in England and Wales to aid in the design of immunisation programs.
Clinical Infectious DiseasesCost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
146 Citations2007Michael B. Rothberg, A. Virapongse +1 more
The cost-effectiveness of the varicella zoster vaccine varies substantially with patient age and often exceeds $100,000 per quality-adjusted life year saved.
VaccineEvaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults
141 Citations2007James M. Pellissier, Marc Brisson +1 more
The zoster vaccine at a price of US$ 150 is likely to be cost-effective for a cohort of immunocompetent U.S. vaccine recipients aged >or=60 years using commonly cited thresholds for judging cost-effectiveness.
VaccineThe burden of Herpes Zoster: A prospective population based study
141 Citations2005Fergus Scott, Rachel Johnson +4 more
The medical, societal and economic burden among patients from 18 general practices in East London, serving 158,716 patients who presented to their general practitioners with acute Herpes Zoster over an 8-month period, was analysed prospectively.
Annals of Internal MedicineCost-Effectiveness of a Vaccine To Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
135 Citations2006John Hornberger, Katherine Robertus
The Shingles Prevention Study examined whether vaccination with a live attenuated VZV vaccine would decrease the incidence and severity of herpes zoster and PHN in adults 60 years of age or older and performed an analysis of the cost-effectiveness of V ZV vaccination in immunocompetent older adults.
Mayo Clinic ProceedingsPotential Effect of Authorization Bias on Medical Record Research
133 Citations1999Steven J. Jacobsen, Zhisen Xia +5 more
These data demonstrate that laws requiring written authorization for research use of the medical record could result in substantial biases in etiologic and outcome studies, the direction and magnitude of which may vary from topic to topic.
Epidemiology and InfectionThe epidemiology of varicella–zoster virus infections: the influence of varicella on the prevalence of herpes zoster
126 Citations1992Geoff P. Garnett, Bryan T. Grenfell
The epidemiological implications of possible immunologically mediated links between patterns of varicella and herpes-zoster incidence in human communities are examined and its consequences need to be assessed in much more depth.
NeurologyHerpes zoster and quality of life
121 Citations1995Eva Lydick, Robert S. Epstein +2 more
This study enrolled 50 patients with herpes zoster from four multispecialty practices, two each from the east and west coasts of the United States, and used the Charlson Comorbidity Index, a commonly used index of comorbidities that was originally developed as a predictor of mortality.
VaccineThe cost-effectiveness of varicella vaccination in Canada
114 Citations2002Marc Brisson, W. John Edmunds
A deterministic realistic age-structured model was used to predict the impact of vaccination on the incidence of varicella and zoster and the preteen vaccination is the only strategy that is deemed cost-effective from a health payer's perspective.
Bulletin of Mathematical BiologyModeling the Effects of Varicella Vaccination Programs on the Incidence of Chickenpox and Shingles
109 Citations1999Matthew C. Schuette
An age-structured epidemiologic—demographic model with vaccination is developed for varicella and zoster and it is found that zoster incidence increases in the first three decades after initiation of a vaccination program, but then it decreases, so the simulations validate the second danger of more zoster cases.
Journal of Pain and Symptom ManagementTreatment of postherpetic neuralgia: a review of therapeutic options
105 Citations2004Charles E. Argoff, Nathaniel P. Katz +1 more
Well-designed, multicenter, controlled clinical trials are needed to develop a treatment algorithm that provides an evidence-based, rational approach to treating PHN.
PainThe prognosis with postherpetic neuralgia
93 Citations1991Peter N.C. Watson, Verna R. Watt +3 more
The most commonly used agents associated with a good outcome were antidepressants, topical capsaicin and analgesics of various kinds, and a group of patients seemed to follow a progressive course and were refractory to all treatments used in this study.
PubMedThe impact of requiring patient authorization for use of data in medical records research.
92 Citations1998Barbara P. Yawn, Roy A. Yawn +3 more
Refusal rates were low for this community practice, however, higher refusal rates in some subgroups, such as older women or patients with mental health concerns, may increase the chance of selection bias in studies involving these patients.
BMJThe management of post-herpetic neuralgia
91 Citations2000Anthony L. Cunningham
This total duration of pain and pain at a single time point (3 months after onset) is suggested to be used as endpoints in clinical studies.
Epidemiology and InfectionSecular trends in the epidemiology of shingles in Alberta
77 Citations2007Marie Russell, Donald Schopflocher +2 more
There was a sex effect and evidence of an age–sex interaction, and the increased rate of shingles in Alberta began before varicella vaccine was licensed or publicly funded in Alberta, and thus cannot be attributed to vaccination.
Journal of InfectionHerpes zoster and its complications in Italy: An observational survey
71 Citations1999Umberto di Luzio Paparatti, Fabio Arpinelli +1 more
It is indicated that annually there are about 200 000 people aged 15 years and over suffering from Herpes zoster in Italy, with a considerable number of cases of post herpetic neuralgia.
Antiviral ResearchAssessment of pain in herpes zoster: lessons learned from antiviral trials
68 Citations1997Robert H. Dworkin, D Carrington +8 more
It is recommended that antiviral efficacy should be evaluated both by distinguishing post-herpetic neuralgia from acute pain and by considering pain as a continuum, and the primary endpoint should address both the prevalence and duration of post-Herpetic Neuralgia.
American Journal of EpidemiologyInterrater Reliability: Completing the Methods Description in Medical Records Review Studies
63 Citations2005Barbara P. Yawn, Peter C. Wollan
This study demonstrates that IRR can be evaluated and summarized, providing important information to the study investigators and to the consumer for assessing the reliability of the data and therefore the validity of the study results and conclusions.
The American journal of geriatric pharmacotherapyGabapentin: a pooled analysis of adverse events from three clinical trials in patients with postherpetic neuralgia
62 Citations2004Bruce Parsons, Leslie Tive +1 more
In this pooled analysis of adverse-event data from 3 clinical trials in patients with PHN, the incidence of peripheral edema was increased when gabapentin was titrated to >or=1800 mg/d.
Epidemiology and InfectionUse of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia
45 Citations2003C. Raina MacIntyre, C. P. Chu +1 more
Herpes zoster has a higher burden of disease than varicella, and must be a component of disease surveillance in order to determine the full impact of vaccination on the epidemiology ofvaricella zoster virus (VZV).
PubMed[Herpes zoster: incidence study among "sentinel" general practitioners].
36 Citations2001Sébastien Czernichow, A. Dupuy +2 more
Drug SafetyTolerability of Treatments for Postherpetic Neuralgia
31 Citations2004Mark W. Douglas, Robert W. Johnson +1 more
Treatment of established PHN is difficult and may require a holistic approach, although tricyclic antidepressants and gabapentin are the systemic agents with the most proven benefit, although opioids such as oxycodone and NMDA receptor antagonists such as ketamine may be useful in some people.
Clinical Microbiology and InfectionEffects of varicella vaccination on herpes zoster incidence
21 Citations2004Stefan Wagenpfeil, A. Neiß +1 more
An increase in zoster incidence after varicella immunisation is possible, but the extent is unknown because of the influence of other factors independent of immunisation.
Human VaccinesVaccination to Prevent Herpes Zoster and Postherpetic Neuralgia
17 Citations2007Michael N. Oxman